Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enclomifene (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics; Proof of concept
- Sponsors Repros Therapeutics
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Results of interim analysis assessing diet and exercise at six months (n=49) presented at The 99th Annual Meeting of the Endocrine Society
- 15 Aug 2016 Six month interim results are published in the Repros Therapeutics Media Release.